Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex

被引:56
作者
Hoozemans, JJM
Veerhuis, R
Rozemuller, AJM
Arendt, T
Eikelenboom, P
机构
[1] VU Univ Med Ctr, Dept Psychiat, Grad Sch Neurosci, Neurosci Res Inst, NL-1007 MB Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Leipzig, Dept Neuroanat, Paul Flechsig Inst Brain Res, Leipzig, Germany
[4] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands
[5] VU Univ Med Ctr, Dept Psychiat, Grad Sch Neurosci Amsterdam, Neurosci Res Inst, Amsterdam, Netherlands
关键词
Alzheimer's disease; amyloid beta; cell cycle; cyclooxygenase-2; neurofibrillary tangles; neuron; p38; MAPK; retinoblastoma protein;
D O I
10.1016/j.nbd.2003.11.028
中图分类号
Q189 [神经科学];
学科分类号
071006 [神经生物学];
摘要
In Alzheimer's disease (AD) brain, increased levels of cyclooxygenase-2 (COX-2), cell cycle markers, and p38 MAP kinase (MAPK) can be detected in neuronal cells. Besides mediating COX-2 expression, p38 MAPK is suggested to mediate cell cycle progression through phosphorylation of the retinoblastoma protein (pRb). In this study, we show that neuronal immunoreactivity for phosphorylated p38 MAPK does not correlate with COX-2 or phosphorylated pRb (ppRb) in control and AD temporal cortex. Immunoreactivity for activated p38 MAPK co-localizes with AT8 immunoreactivity and increases with the occurrence of neurofibrillary tangles and plaques. On the other hand, COX-2 immunoreactivity co-localizes and correlates with ppRb immunoreactivity in pyramidal neurons. COX-2 and ppRb do not co-localize with AT8 and decrease with increasing pathology. These results suggest that p38 MAPK does not mediate COX-2 expression and pRb inactivation, which are involved in cellular changes in pyramidal neurons early in AD pathogenesis. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:492 / 499
页数:8
相关论文
共 34 条
[1]
Andreasson KI, 2001, J NEUROSCI, V21, P8198
[2]
Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization [J].
Arendt, T .
NEUROSCIENCE, 2001, 102 (04) :723-765
[3]
STAGING OF ALZHEIMERS-DISEASE-RELATED NEUROFIBRILLARY CHANGES [J].
BRAAK, H ;
BRAAK, E .
NEUROBIOLOGY OF AGING, 1995, 16 (03) :271-278
[4]
NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[5]
Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity [J].
Chen, C ;
Magee, JC ;
Bazan, NG .
JOURNAL OF NEUROPHYSIOLOGY, 2002, 87 (06) :2851-2857
[6]
Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo [J].
Eli, Y ;
Przedecki, F ;
Levin, G ;
Kariv, N ;
Raz, A .
BIOCHEMICAL PHARMACOLOGY, 2001, 61 (05) :565-571
[7]
Interleukin-1β induces cyclooxygenase-2 and prostaglandin E2 synthesis in human neuroblastoma cells:: Involvement of p38 mitogen-activated protein kinase and nuclear factor-κB [J].
Fiebich, BL ;
Mueksch, B ;
Boehringer, M ;
Hüll, M .
JOURNAL OF NEUROCHEMISTRY, 2000, 75 (05) :2020-2028
[8]
COX-2 expression and cell cycle progression in human fibroblasts [J].
Gilroy, DW ;
Saunders, MA ;
Wu, KK .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2001, 281 (01) :C188-C194
[9]
Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease [J].
Ho, L ;
Purohit, D ;
Haroutunian, V ;
Luterman, JD ;
Willis, F ;
Naslund, J ;
Buxbaum, JD ;
Mohs, RC ;
Aisen, PS ;
Pasinetti, GM .
ARCHIVES OF NEUROLOGY, 2001, 58 (03) :487-492
[10]
Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain [J].
Hoozemans, JJM ;
Rozemuller, AJM ;
Janssen, I ;
De Groot, CJA ;
Veerhuis, R ;
Eikelenboom, P .
ACTA NEUROPATHOLOGICA, 2001, 101 (01) :2-8